

January 22, 2025

DCS-CRD BSE Limited First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400001 Fax No.2272 3121/2037/2039 Stock Code: 543213	Listing Compliance National Stock Exchange of India Ltd. Exchange Plaza, 5 th Floor Plot No. C/1, 'G' Block, Bandra- Kurla Complex Bandra East Mumbai 400051 Fax No.2659 8237/8238 Stock Code: ROSSARI
--	---

Dear Sir/Madam,

Subject.: Q3 FY25 Press Release

Please find enclosed a copy of the Press Release for the quarter and nine months ended December 31, 2024.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,

For Rossari Biotech Limited

**Parul
Gupta**

Digitally signed by
Parul Gupta
Date: 2025.01.22
19:51:02 +05'30'



Parul Gupta
Head - Company Secretary & Legal
Membership No.: A38895

Encl.: as above

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company), CIN: L24100MH2009PLC194818

Regd. Office : 201 A - B, 2nd Floor, Akruti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg (W), Mumbai - 400078, India. **T** : +91-22-6123 3800 **F** : +91-22-2579 6982

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. **T** : 0260-669 3000

: Plot No. D3/24/3, Opposite Yokohama Tyre, Phase III, G.I.D.C Dahej, Village Galenda, Taluka Vagra, Bharuch-Gujarat - 392130, India. **T** : +91 2641-661621

info@rossari.com

www.rossari.com



HOME, PERSONAL CARE AND PERFORMANCE CHEMICALS



TEXTILE SPECIALITY CHEMICALS



ANIMAL HEALTH AND NUTRITION



Rossari Biotech Limited

Corporate Office: 201 A & B Ackruti Corporate Park LBS Marg Next to G. E. Gardens, Kanjurmarg
West, Mumbai, Maharashtra 400078

Rossari Biotech announces Q3 FY25 results

Q3 FY25

- **Revenues at Rs. 512.7 Cr, up 10.5% YoY**
- **EBITDA at Rs. 64.8 Cr, up 1.7% YoY**
- **PAT at Rs. 31.7 Cr, down 7.8% YoY**

Mumbai, January 21, 2025: Rossari Biotech Limited (Rossari), a Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries, has announced its financial results for the quarter ended December 31, 2024.

Consolidated: Q3 FY25 performance overview compared with Q3 FY24

- Revenue from operations grew 10.5% to Rs. 512.7 crore as compared to Rs. 463.8 crore
- EBITDA improved by 1.7% to Rs. 64.8 crore from Rs. 63.7 crore
 - o EBITDA margin at 12.6% as against 13.7%
- PAT decreased by 7.8% to Rs. 31.7 crore from Rs. 34.4 crore
- EPS (Diluted) stood at Rs. 5.7* as against Rs. 6.2*

Consolidated: 9M FY25 performance overview compared with 9M FY24

- Revenue from operations stood at Rs. 1,500.7 crore as against Rs. 1,357.8 crore, up 10.5%
- EBITDA increased by 5.7% to Rs. 195.6 crore as against Rs. 185.0 crore
 - o EBITDA margin at 13.0% as against 13.6%
- PAT higher by 5.5% to Rs. 101.9 crore as against Rs. 96.6 crore
- EPS (Diluted) stood at Rs. 18.4* as against Rs. 17.5*

Note:

- 1) All figures, unless mentioned otherwise, are on a consolidated basis
- 2) * EPS not annualized

Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said

“We have navigated a dynamic operating environment in Q3 FY25, delivering resilient performance despite softer domestic market conditions. All business segments registered Y-o-Y volume growth during the quarter, with exports playing a pivotal role in driving overall performance amidst domestic challenges.

During the quarter, HPPC grew by 10%, TSC by 15%, and AHN by 12% Y-o-Y, reflecting the dedicated efforts of our team in a challenging business environment. We have continued to target customers in both new and existing geographies, delivering strong performance in international markets. Our international business registered a Y-o-Y growth of 21% during the quarter and for the nine months, grew by 28%, providing support to overall performance amidst softer domestic growth. By targeting key markets, investing in technology, enhancing capacities, and introducing innovative products, we consistently strengthen our global footprint and position ourselves for sustained growth.

Our gross margins improved during the quarter, supported by a favorable product mix and operational efficiencies. However, EBITDA margins were slightly lower this quarter due to ongoing investments in future initiatives. Despite this, we remain confident that higher operating leverage will enable us to improve margins over time. New capacities are expected to be commissioned soon, with projects being rolled out in a phased manner over the coming quarters. These expansions will further strengthen our ability to serve high-growth segments effectively.

Innovation and sustainability remain at the core of our strategy as we pioneer intelligent, eco-friendly solutions tailored to evolving customer needs. Supported by robust R&D capabilities and a strong focus on operational excellence, we are well-equipped to capitalize on emerging opportunities and drive long-term growth. Our agile manufacturing setup and diversified product portfolio provide a strong foundation for delivering sustainable value to all our stakeholders.”

Key Developments

Progress on Capacity Expansion Projects:

- The Company is advancing its capacity expansion initiatives at the Dahej facility and through Unitop Chemicals to meet the growing demand for specialty chemicals across key segments
 - These projects are expected to be commissioned in the coming quarters, strengthening the Company's ability to cater to high-growth markets and expand its reach in both domestic and international geographies
-

< Ends >

Note: Home, Personal Care and Performance Chemicals (HPPC); Textile Specialty Chemicals (TSC); Animal Health and Nutrition (AHN)

About Rossari Biotech Limited:

Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates strategically located manufacturing facilities at Silvassa and Dahej. The Company offers tailor-made solutions for Home, Personal Care and Performance chemicals (HPPC), Textile speciality chemicals and Animal Health and Nutrition (AHN). With differentiated product offerings, Rossari caters to an array of applications across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Chemicals, Performance Chemicals, the Animal Health and Nutrition and Pet Care businesses. The Company has an extensive and a dedicated network of distributors spread all over India.

For more information, please visit www.rossari.com OR contact:

Ketan Sablok

Rossari Biotech Limited
Tel: +91 22 6123 3800
Email: ketan.sablok@rossari.com

Anoop Poojari / Mitesh Jain

CDR India
Tel: +91 98330 90434 / 96194 44691
Email: anoop@cdr-india.com /
mitesh@cdr-india.com

DISCLAIMER:

Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Limited in the press release ("forward-looking statements"), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward-looking statements only speak as at the date the press release is provided to the recipient and Rossari Biotech Limited is not under any obligation to update or revise such forward-looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this press release or that this press release is suitable for the recipient's purposes. The delivery of this press release does not imply that the information herein is correct as at any time subsequent to the date hereof and Rossari Biotech Limited has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof.